LIBRETTO-431: Selpercatinib in treatment (Tx)-naive patients with RET fusion-positive (RET plus ) non-small cell lung cancer (NSCLC)

被引：2

作者：

Loong, H. H. F. ^{[1
]}

Goto, K. ^{[2
]}

Elamin, Y. Y. ^{[3
]}

Solomon, B. ^{[4
]}

Santini, F. C. ^{[5
]}

Soldatenkova, V. ^{[6
]}

Sashegyi, A. ^{[6
]}

Lin, A. Bence ^{[6
]}

Lin, B. K. ^{[6
]}

Wolf, J. ^{[7
]}

Oxnard, G. R. ^{[8
]}

Zhou, C. ^{[9
]}

Drilon, A. ^{[10
]}

Park, K. ^{[11
]}

机构：

[1] Chinese Univ Hong Kong, Clin Oncol, Hong Kong, Peoples R China

[2] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan

[3] Univ Texas MD Anderson Canc Ctr, Thorac Head & Neck Med Oncol, Houston, TX 77030 USA

[4] Peter MacCallum Canc Ctr, Dept Med Oncol, Melbourne, Vic, Australia

[5] Hosp Sirio Libanes, Ctr Oncol, Sao Paulo, Brazil

[6] Eli Lilly & Co, Oncol, Indianapolis, IN 46285 USA

[7] Univ Hosp Cologne, Oncol, Cologne, Germany

[8] Dana Farber Canc Inst, Med Oncol, Boston, MA 02115 USA

[9] Shanghai Pulm Hosp, Dept Oncol, Shanghai, Peoples R China

[10] Mem Sloan Kettering Evelyn H Lauder Breast Ctr, Early Drug Dev Serv, New York, NY USA

[11] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr SMC, Div Heamatol Oncol, Seoul, South Korea

来源：

ANNALS OF ONCOLOGY | 2020年 / 31卷

关键词：

D O I：

10.1016/j.annonc.2020.08.1727

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1413TiP

引用

页码：S893 / S893

页数：1

共 50 条

[1] LIBRETTO-431: Selpercatinib in Treatment-Naive Patients with RET Fusion-Positive Non-Small Cell Lung Cancer (NSCLC).
Goto, K.
Wolf, J.
Elamin, Y.
Santini, F.
Soldatenkova, V.
Sashegyi, A.
Lin, A. Bence
Lin, B.
Novello, S.
Arriola Aperribay, E.
Perol, M.
Loong, H.
Drilon, A.
Park, K.
Solomon, B.
Zhou, C.
[J]. JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S228 - S229
[2] Intracranial outcomes of 1L selpercatinib in advanced RET fusion-positive NSCLC: LIBRETTO-431 study.
Perol, Maurice
Goto, Koichi
Solomon, Benjamin J.
Park, Keunchil
Nadal, Ernest
Bria, Emilio
Martin, Claudio
Bar, Jair
Williams, Justin
Puri, Tarun
Li, Jian
Uh, Minji
Lin, Boris K.
Zhou, Caicun
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[3] Health-related quality of life (HRQoL) and symptoms in LIBRETTO-431 patients with RET fusion-positive advanced non-small-cell lung cancer (NSCLC)
Zhou, Caicun
Novello, Silvia
Garrido, Pilar
Dooms, Christophe Alfons
Alexander, Jorge Arturo Alatorre
Reinmuth, Niels
Gilligan, Adrienne M.
Payakachat, Nalin
Cocks, Kim
Worthy, Gill
Goto, Koichi
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[4] Intracranial Efficacy of Selpercatinib in RET Fusion-Positive Non-Small Cell Lung Cancers on the LIBRETTO-001 Trial
Subbiah, Vivek
Gainor, Justin F.
Oxnard, Geoffrey R.
Tan, Daniel S. W.
Owen, Dwight H.
Cho, Byoung Chul
Loong, Herbert H.
McCoach, Caroline E.
Weiss, Jared
Kim, Yu Jung
Bazhenova, Lyudmila
Park, Keunchil
Daga, Haruko
Besse, Benjamin
Gautschi, Oliver
Rolfo, Christian
Zhu, Edward Y.
Kherani, Jennifer F.
Huang, Xin
Kang, Suhyun
Drilon, Alexander
[J]. CLINICAL CANCER RESEARCH, 2021, 27 (15) : 4160 - 4167
[5] Sorafenib treatment for patients with RET fusion-positive non-small cell lung cancer
Horiike, Atsushi
Takeuchi, Kengo
Uenami, Takeshi
Kawano, Yuko
Tanimoto, Azusa
Kaburaki, Kyohei
Tambo, Yuichi
Kudo, Keita
Yanagitani, Noriko
Ohyanagi, Fumiyoshi
Motoi, Noriko
Ishikawa, Yuichi
Horai, Takeshi
Nishio, Makoto
[J]. LUNG CANCER, 2016, 93 : 43 - 46
[6] Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer
Drilon, A.
Oxnard, G. R.
Tan, D. S. W.
Loong, H. H. F.
Johnson, M.
Gainor, J.
McCoach, C. E.
Gautschi, O.
Besse, B.
Cho, B. C.
Peled, N.
Weiss, J.
Kim, Y. -J.
Ohe, Y.
Nishio, M.
Park, K.
Patel, J.
Seto, T.
Sakamoto, T.
Rosen, E.
Shah, M. H.
Barlesi, F.
Cassier, P. A.
Bazhenova, L.
De Braud, F.
Garralda, E.
Velcheti, V.
Satouchi, M.
Ohashi, K.
Pennell, N. A.
Reckamp, K. L.
Dy, G. K.
Wolf, J.
Solomon, B.
Falchook, G.
Ebata, K.
Nguyen, M.
Nair, B.
Zhu, E. Y.
Yang, L.
Huang, X.
Olek, E.
Rothenberg, S. M.
Goto, K.
Subbiah, V.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (09): : 813 - 824
[7] Intracranial activity of selpercatinib (LOXO-292) in RET fusion-positive non-small cell lung cancer (NSCLC) patients on the LIBRETTO-001 trial.
Subbiah, Vivek
Gainor, Justin F.
Oxnard, Geoffrey R.
Tan, Daniel Shao-Weng
Owen, Dwight Hall
Cho, Byoung Chul
Loong, Herbert H. F.
McCoach, Caroline Elizabeth
Weiss, Jared
Kim, YuJung
Bazhenova, Lyudmila
Park, Keunchil
Daga, Haruko
Besse, Benjamin
Gautschi, Oliver
Ng, Sarah
Huang, Xin
Drilon, Alexander E.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[8] Updated overall efficacy and safety of selpercatinib in patients with RET fusion-positive non-small-cell lung cancer (NSCLC): LIBRETTO-001 study
Besse, B.
Drillon, A. E.
Solomon, B. J.
Subbiah, V.
Tan, D. S. -W.
Park, K.
De Braud, F. G.
Alonso, G.
Wolf, J.
Soldatenkova, V.
Lin, A. K.
French, P.
Goto, K.
Gautschi, O.
[J]. SWISS MEDICAL WEEKLY, 2021, 151 : 34 - 34
[9] SORAFENIB IN PATIENTS WITH RET FUSION-POSITIVE NON-SMALL CELL LUNG CANCER
Horiike, Atsushi
Takeuchi, Kengo
Uenami, Takeshi
Kawano, Yuko
Tanimoto, Azusa
Kaburaki, Kyohei
Kobayashi, Hiroshi
Gyotoku, Hiroshi
Nishizawa, Hironari
Tambo, Yuichi
Nakatomi, Katsumi
Yanagitani, Noriko
Ohyanagi, Fumiyoshi
Hagiwara, Sachiko
Motoi, Noriko
Ishikawa, Yuichi
Horai, Takeshi
Nishio, Makoto
[J]. JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S898 - S898
[10] Patient-reported outcomes of first-line selpercatinib versus chemotherapy with or without pembrolizumab in RET fusion-positive advanced non-small cell lung cancer: Interim analysis of LIBRETTO-431
Goto, K.
Novello, S.
Garrido Lopez, P.
Dooms, C.
Alatorre Alexander, J. A.
Reinmuth, N.
Gilligan, A.
Payakachat, N.
Lin, A.
Cocks, K.
Worthy, G.
Zhou, C.
[J]. ANNALS OF ONCOLOGY, 2023, 34 : S1654 - S1655

← 1 2 3 4 5 →